Marc N. Casper, Chairman and CEO of Thermo Fisher Scientific Inc. (NYSE:TMO), filed a Form 4 on August 24, 2026, disclosing the exercise of stock options and subsequent sales of common stock on August 20 and August 21, 2026.

Key Highlights

  • Two option exercises: Casper exercised 10,000 stock options on each of August 20 and August 21, 2026, at an exercise price of $309.63 per share.
  • Shares sold on August 20: A total of 9,000 shares were sold across nine tranches at weighted average prices ranging from $625.45 to $633.99 per share.
  • Shares sold on August 21: A total of 10,000 shares were sold across five tranches at weighted average prices ranging from $625.46 to $629.10 per share.
  • Remaining direct ownership: Following all reported transactions, Casper directly held 123,925.358 shares of common stock.
  • Indirect holdings: An additional 11,300 shares are held indirectly by the Alison Casper 2020 Irrevocable Trust and 5,000 shares by the MNC 2020 Irrevocable Trust, with Casper disclaiming beneficial ownership except to the extent of any pecuniary interest.
  • Rule 10b5-1 plan: According to the filing, all sales were effected pursuant to a Rule 10b5-1 trading plan adopted by Casper on April 27, 2026.
  • Remaining options: After both exercises, 275 stock options with an exercise price of $309.63 and an expiration date of February 25, 2027, remained outstanding.

Casper's Option Exercises and Share Sales at Thermo Fisher Scientific

According to the filing, Casper exercised a total of 20,000 stock options over two consecutive days, acquiring shares at the option exercise price of $309.63. The filing notes the underlying option vested in four equal installments on February 25, 2021, 2022, 2023, and 2024. Following each day's exercise, Casper sold shares in multiple tranches at weighted average prices, with all transactions attributed by the filing to a Rule 10b5-1 trading plan adopted on April 27, 2026.

On August 20, 2026, after exercising 10,000 options, Casper disposed of 9,000 shares across nine separate sale transactions. Prices ranged from a weighted average of $625.45 to $633.99 per share, with individual transaction ranges disclosed in the filing's footnotes. The filing states that full information on shares sold at each separate price within those ranges is available upon request to Thermo Fisher Scientific, any security holder, or the SEC staff.

On August 21, 2026, an additional 10,000 options were exercised and 10,000 shares were sold across five tranches at weighted average prices from $625.46 to $629.10. Following all transactions on both days, Casper's direct beneficial ownership stood at 123,925.358 shares, with an additional 16,300 shares held indirectly through two irrevocable trusts. The filing was signed by Melodie T. Morin as Attorney-in-Fact for Marc N. Casper.

What Was Disclosed

The Form 4 discloses that Marc N. Casper, Chairman and CEO, exercised 20,000 stock options at $309.63 per share and sold 19,000 shares of Thermo Fisher Scientific common stock on August 20 and 21, 2026, under a pre-established Rule 10b5-1 trading plan.